Early and Supernormal Vascular Aging: Clinical Characteristics and Association With Incident Cardiovascular Events

Rosa Maria Bruno1, Peter M Nilsson2, Gunnar Engström2

  • 1From the INSERM, U970, Paris Cardiovascular Research Center-PARCC, France (R.M.B., J.-P.E., P.B., S.L.).

Insights

Individuals with supernormal vascular aging, characterized by a younger vascular age than chronological age, experience fewer cardiovascular events. This finding validates the concept and may reveal protective pathways for healthy aging.

Area of Science:

  • Cardiovascular Health
  • Aging Research
  • Vascular Biology

Background:

  • Pulse wave velocity (PWV) is a key indicator of vascular aging.
  • PWV may also identify individuals with 'supernormal' vascular aging.
  • Defining and validating supernormal vascular aging is crucial for understanding cardiovascular risk.

Purpose of the Study:

  • To test the hypothesis that a large difference between chronological and vascular age (Δ-age) is linked to lower cardiovascular event rates.
  • To define and validate the concept of supernormal vascular aging using prospective data.
  • To investigate the association between vascular aging categories and cardiovascular event risk.

Main Methods:

  • Vascular age was calculated using a regression model incorporating PWV and cardiovascular risk factors.
  • Δ-age was computed as chronological age minus vascular age.
  • Cardiovascular event risk was analyzed in the Malmö Diet and Cancer Study cohort based on Δ-age percentiles.

Main Results:

  • A significant inverse association was found between Δ-age and cardiovascular events (P<0.01).
  • Supernormal vascular aging (Δ-age > 6.8 years) showed a reduced risk of cardiovascular events (HR, 0.59).
  • Early vascular aging (Δ-age < -5.7 years) demonstrated an increased risk (HR, 2.70), particularly for coronary events.

Conclusions:

  • This study provides the first prospective validation of the clinical significance of supernormal vascular aging.
  • The findings support the concept that a younger vascular age confers protection against cardiovascular events.
  • Further research into supernormal vascular aging may uncover novel protective mechanisms and preventive strategies.

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
217
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
312
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
541
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
216
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
120
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
175